A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01387958
(Terminated early due to futility)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Written informed consent.
Male and female subjects 18 to 65 years of age with hepatitis C infections (genotypes 1, 2 or 3).
No prior therapy or inadequate response to therapy for hepatitis C.
Weight at least 50 kg and body mass index (BMI) within 18 - 35 kg/m2.
Use of other investigational drugs within at least 30 days of enrollment
Women of child-bearing potential.
Other protocol-defined inclusion/exclusion criteria apply